Established in Shanghai
Category I Major Innovative Biologic Drug during the 11th Five-Year Plan period-PUK
First-in-class/best-in-class biological product portfolio
Perfusion culture technology platform for mammalian cells
Commercialization platforms which integrates
The research and development, manufacturing, and sales.
Field of Disease
Tasly Biopharma focuses on the development of biologic drugs in three major therapeutic areas of cardiovascular diseases, oncology and autoimmune diseases, and alimentary tract and metabolism, and has a preferred product portfolio of more than 19 biological assets capable of continuous development.
We have the new generation of fibrin-specific thrombolytic drug, PUK, available on the market and other products that are currently under development such as acute ischemic stroke (AIS) B1140, acute pulmonary embolism (APE) B1448 and PCSK9 monoclonal antibody B1655 for targeted treatment of hypercholesterolemia.
Tasly Biopharma focuses on the development of new drugs such as monoclonal antibodies, bispecific antibodies, oncolytic virus, and immunotherapeutic products, and the product varieties under development include a fully-human EGFR-targeted monoclonal antibody SY101 for the treatment of advanced colorectal cancer and oncolytic virus product T601 for the treatment of advanced malignant solid tumors.
The new generation of fibrin-specific thrombolytic drugs
An integrated commercial platform that covers all life cycles of biological drugs
Complete marketing network
Open-access biologics R&D platform
The manufacturing capabilities that are based on the perfusion culture technology
talent is the root that drives scientific and technological innovation
We will build a biopharmaceutical company that continues to innovate in key therapeutic areas. In the process, we will never stop looking for like-minded colleagues to fight and grow together.
Mission and Vision Management Team
Board of Directors
R&D and Innovation
Field of Disease
Manufacturing Process Manufacturing Operations